Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

Cancers of the stomach and esophagus are among the most challenging cancers of the GI
tract to treat, associated with poor median survivals for metastatic disease and significant …

Purpose Increased hepatocyte growth factor/MET signaling is associated with poor
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)–targeted …

Gastric cancer is an aggressive disease that continues to have a daunting impact on global
health. Despite an overall decline in incidence over the last several decades, gastric cancer …

The HGF/MET signaling pathway is critical in mediating a wide range of normal
physiological functions including embryological development, wound healing, and tissue …

Abstract The N-methyl-N′-nitroso-guanidine human osteosarcoma transforming gene
(MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular …

MET and its ligand HGF are involved in many biological processes, both physiological and
pathological, making this signaling pathway an attractive therapeutic target in oncology …

Gastric cancer is an aggressive disease often diagnosed at an advanced stage. Despite
improvements in surgical and adjuvant treatment approaches, gastric cancer remains a …

Simple Summary Secondary amplifications/copy number changes of the gene MET (MET
protocol oncogene) play a significant role in the development of resistance to targeted drugs …

Background: The aim of this study was to compare gene copy number (GCN) and protein
expression of MET and to evaluate their prognostic roles in gastric carcinomas. Methods …